New combo therapy aims to shrink throat tumors before standard care
NCT ID NCT07267338
First seen Jan 11, 2026 · Last updated May 15, 2026 · Updated 25 times
Summary
This phase 2 trial tests whether giving pembrolizumab (an immunotherapy) plus MRG-003 (a targeted drug) before standard chemoradiation can improve outcomes for people with advanced, EBV-related nasopharyngeal cancer. About 35 participants will receive the combination for 3 cycles, then standard treatment, followed by more pembrolizumab. The main goal is to see how many patients have a complete clinical response before starting standard therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NPC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Wuhan Xiehe Hospital
Wuhan, Hubei, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.